NEPTAZANE
Pronunciation: meth-a-ZOL-a-mide


What it isCarbonic anhydrase inhibitor; glaucoma.
Why this oneHas less renal effect and is often better tolerated than acetazolamide at equivalent pressure reduction.
What limits itParesthesia, fatigue and metabolic acidosis persist; it is a sulfonamide.
Animated chart of estimated U.S. prescriptions per year, Glaucoma medicines (1900–2026). Methazolamide enters in 1959 (estimated).
Principal riskParaesthesia and metabolic acidosis
Sulfonamide-derived drug (non-antibacterial) — label warns
No N4 aromatic amine, no N1 heterocycle: cross-reactivity after a sulfonamide-antimicrobial reaction is unlikely — sulfa-allergic patients reacted to sulfonamide non-antibiotics at 9.9% vs 1.6%, less often than to penicillin. The label warns anyway.
Open the sulfonamide hypersensitivity presentation → · sources [n] are on its References slide.
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Glaucoma (elevated intraocular pressure) | adult | 50 mg BID-TID | 50-100 mg BID-TID | 100 mg TID |
Renal Contraindicated in marked kidney disease or dysfunction
Hepatic Contraindicated in marked liver disease/dysfunction; may precipitate hepatic encephalopathy in cirrhosis
Available strengths
Pregnancy Category C; teratogenic (skeletal anomalies) in rats; use only if benefit justifies fetal risk
Lactation Undefined
Generic entry1993
Open Methazolamide in the interactive console ↗

Open Methazolamide in the interactive console ↗